Vanguard Group Inc. Boosts Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Vanguard Group Inc. grew its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 0.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,187,420 shares of the biotechnology company’s stock after buying an additional 7,226 shares during the quarter. Vanguard Group Inc. owned 5.42% of Aldeyra Therapeutics worth $21,292,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. purchased a new stake in shares of Aldeyra Therapeutics in the second quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its stake in shares of Aldeyra Therapeutics by 47,866.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 4,308 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth approximately $57,000. UBS Group AG boosted its stake in shares of Aldeyra Therapeutics by 256.0% in the first quarter. UBS Group AG now owns 6,408 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 4,608 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of Aldeyra Therapeutics in the third quarter worth approximately $68,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $4.25 on Friday. The stock’s fifty day moving average is $3.51 and its two-hundred day moving average is $3.33. The firm has a market capitalization of $250.33 million, a P/E ratio of -6.64 and a beta of 1.51. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.42 and a fifty-two week high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. As a group, sell-side analysts forecast that Aldeyra Therapeutics, Inc will post -0.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. StockNews.com raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 29th. Oppenheimer raised Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, April 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd.

Insider Activity

In other news, CEO Todd C. Brady sold 97,914 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total value of $320,178.78. Following the transaction, the chief executive officer now owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Bruce Greenberg sold 13,201 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the sale, the insider now owns 120,699 shares in the company, valued at approximately $411,583.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Todd C. Brady sold 97,914 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.27, for a total value of $320,178.78. Following the completion of the sale, the chief executive officer now owns 1,556,622 shares in the company, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. Insiders have acquired a total of 355,933 shares of company stock valued at $1,473,245 in the last quarter. Insiders own 7.30% of the company’s stock.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.